← Leaderboards
Steven D Gore
Johns Hopkins University
$7,773,366
Attributed
$7,773,366
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–15$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$7,773,366 · 6
By mechanism
R01$5,005,546 · 3
K24$1,708,881 · 1
R21$1,058,939 · 2
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- William B. Guggino$17,014,421
- Pamela L. Zeitlin$9,680,949
- Manuel Hidalgo$7,987,249
- Nancy E Davidson$32,860,580
- Hugo W Moser$5,176,943
Others in their field
Top investigators on “Azacitidine”
- Dana Dolinoy · University Of Michigan At Ann Arbor$5,320,788
- Steven A Belinsky · Lovelace Biomedical &Environmental Res$5,172,501
- Lewis Silverman · Mount Sinai School Of Medicine Of Nyu$5,107,998
- Mark J Ratain · University Of Chicago$4,695,781
- William C Aird · Harvard University (Medical School)$4,111,661
- Carlo M Croce · Thomas Jefferson University$4,057,634
Research focus
AzacitidineClinical ResearchDysmyelopoietic SyndromesHistonesNeoplasm /Cancer ChemotherapyGenesOralLeukemia, Myelocytic, AcuteSchedulePromotor (Genetics)Ms-275Myeloproliferative DiseaseDesignMethylationCancer CellPharmaceutical PreparationsDoseEpigenetic ProcessInhibitor/AntagonistResponseGene SilencingIn VitroRelapseBase
Grant awards (25)
Targeting Epigenomics in Myeloid Neoplasms$197,100
K24 · FY2015 · CA · contact PI
Targeting Epigenomics in Myeloid Neoplasms$197,100
K24 · FY2014 · CA · contact PI
Targeting Epigenomics in Myeloid Neoplasms$197,100
K24 · FY2013 · CA · contact PI
Targeting Epigenomics in Myeloid Neoplasms$197,100
K24 · FY2012 · CA · contact PI
Targeting Epigenomics in Myeloid Neoplasms$196,885
K24 · FY2011 · CA · contact PI
Mechanism of combined 'epigenetic therapy' in myeloid malignancies$486,728
R01 · FY2009 · CA · contact PI
Targeting Epigenomics in Myeloid Neoplasms$150,160
K24 · FY2009 · CA · contact PI
Mechanism of combined 'epigenetic therapy' in myeloid malignancies$476,730
R01 · FY2008 · CA · contact PI
Arsenic Trioxide in Primary Curative APL Therapy$420,352
R01 · FY2008 · CA · contact PI
Targeting Epigenomics in Myeloid Neoplasms$147,360
K24 · FY2008 · CA · contact PI
Mechanism of combined 'epigenetic therapy' in myeloid malignancies$520,405
R01 · FY2007 · CA · contact PI
Arsenic Trioxide in Primary Curative APL Therapy$419,060
R01 · FY2007 · CA · contact PI
Targeting Epigenomics in Myeloid Neoplasms$144,640
K24 · FY2007 · CA · contact PI
Arsenic Trioxide in Primary Curative APL Therapy$459,578
R01 · FY2006 · CA · contact PI
Targeting Epigenomics in Myeloid Neoplasms$141,999
K24 · FY2006 · CA · contact PI
Arsenic Trioxide in Primary Curative APL Therapy$466,191
R01 · FY2005 · CA
5-Azacytidine and MS-275 in Myeloid Malignancies$258,611
R21 · FY2005 · CA
Targeting Epigenomics in Myeloid Neoplasms$139,437
K24 · FY2005 · CA
Arsenic Trioxide in Primary Curative APL Therapy$551,295
R01 · FY2004 · CA
5-Azacytidine and MS-275 in Myeloid Malignancies$284,646
R21 · FY2004 · CA
DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION$419,652
R01 · FY2002 · CA
DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION$407,422
R01 · FY2001 · CA
CLINICAL HISTONE DEACETYLASE INHIBITION AND RETINOIDS$257,513
R21 · FY2001 · CA
DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION$378,133
R01 · FY2000 · CA
CLINICAL HISTONE DEACETYLASE INHIBITION AND RETINOIDS$258,169
R21 · FY2000 · CA